On August 31, Moderna, Inc. rose 3.44% in regular trading, trading at approximately $142.47/share, with turnover of $547 million. The stock reversed earlier pre-market weakness driven by convertible note dilution concerns and negative sentiment from BioNTech's cancer vaccine clinical setback.

On the news front, Argus Research upgraded Moderna from Hold to Buy with a $180 price target, becoming the fifth institution to raise its rating in recent sessions. Previously, Barclays lifted its target from $48 to $125, while Bank of America and other major banks also significantly raised their price targets. Analysts noted that following the successful Phase 3 results of the company's personalized mRNA melanoma cancer vaccine developed in partnership with Merck, the stock remains more than 70% below its historical highs, suggesting further upside potential as confirmatory data emerges.

The broader backdrop includes the company's $2.6 billion zero-coupon convertible senior notes offering due 2032, which initially pressured shares. However, institutional conviction around the mRNA cancer vaccine platform, which reduced melanoma recurrence or death risk by 44% in trials, appears to have outweighed dilution concerns during the regular session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)